Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Autor: Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina M. Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O'Malley

Publikováno v: Scientia

Bevacizumab; Folate receptor alpha; Platinum-resistant ovarian cancer Bevacizumab; Receptor de folato alfa; Cáncer de ovario resistente al platino Bevacizumab; Receptor de folat alfa; Càncer d'ovari resistent al platí Purpose Evaluate the antitumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9563699908903c82ae422d0b10f7eaa2
https://hdl.handle.net/11351/9113

Perceived importance of weight loss and exercise among endometrial cancer survivors with overweight or obesity: Implications for lifestyle modification interventions.

Autor: Tagai EK; Cancer Prevention and Control Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA., Mantia-Smaldone GM; Division of Gynecologic Oncology Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA., Belfiglio A; Cancer Prevention and Control Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA., Chu CS; Division of Gynecologic Oncology Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA., Lapitan E; Cancer Prevention and Control Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA., Santos H; Cancer Prevention and Control Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA.; Department of Epidemiology and Biostatistics Dornsife School of Public Health Drexel University Philadelphia Pennsylvania USA., Hernandez E; Obstetrics, Gynecology, and Reproductive Sciences Lewis Katz School of Medicine at Temple University Philadelphia Pennsylvania USA., Sarwer DB; College of Public Health Center for Obesity Research and Education Temple University Philadelphia PA USA., Miller SM; Cancer Prevention and Control Fox Chase Cancer Center/Temple University Health System Philadelphia Pennsylvania USA.

Publikováno v: Obesity science & practice [Obes Sci Pract] 2023 Jul 31; Vol. 9 (6), pp. 661-669. Date of Electronic Publication: 2023 Jul 31 (Print Publication: 2023).

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.

Autor: Cronin S; Department of Obstetrics and Gynecology, Albert Einstein Medical Center, Philadelphia, PA 19141, USA., Ahmed N; Department of Obstetrics and Gynecology, Albert Einstein Medical Center, Philadelphia, PA 19141, USA., Craig AD; Department of Surgical Oncology, Division of Gynecology Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., King S; Department of Surgical Oncology, Division of Gynecology Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Huang M; Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Chu CS; Department of Surgical Oncology, Division of Gynecology Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Mantia-Smaldone GM; Department of Surgical Oncology, Division of Gynecology Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Publikováno v: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2022 Feb 22; Vol. 12 (3). Date of Electronic Publication: 2022 Feb 22.

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Autor: O'Malley DM; The Ohio State University, Columbus, OH, United States. Electronic address: David.O'Malley@osumc.edu., Matulonis UA; Dana Farber Cancer Institute, Boston, MA, United States. Electronic address: Ursula_Matulonis@dfci.harvard.edu., Birrer MJ; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, United States. Electronic address: mbirrer@uab.edu., Castro CM; Massachusetts General Hospital, Boston, MA, United States. Electronic address: Castro.Cesar@mgh.harvard.edu., Gilbert L; McGill University Health Centre, Montreal, QC, Canada. Electronic address: lucy.gilbert@mcgill.ca., Vergote I; Leuven Cancer Institute, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be., Martin LP; University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Lainie.Martin@uphs.upenn.edu., Mantia-Smaldone GM; Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address: Gina.Mantia-Smaldone@fccc.edu., Martin AG; Clinica Universidad de Navarra, Madrid, Spain. Electronic address: agonzalezma@unav.es., Bratos R; MD Anderson Cancer Center Madrid, Madrid, Spain. Electronic address: rbratosl@hospiten.com., Penson RT; Massachusetts General Hospital, Boston, MA, United States. Electronic address: Penson.Richard@mgh.harvard.edu., Malek K; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: karim.malek@immunogen.com., Moore KN; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: Kathleen-Moore@ouhsc.edu.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2020 May; Vol. 157 (2), pp. 379-385. Date of Electronic Publication: 2020 Feb 18.

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Autor: Andersen CL; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Molecular Pharmacology Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Sikora MJ; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Boisen MM; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.; Department of Obstetrics, Gynecology, & Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania., Ma T; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Christie A; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Tseng G; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Park Y; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Luthra S; Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania., Chandran U; Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania., Haluska P; Oncology, Merck Research Laboratories, Rahway, New Jersey., Mantia-Smaldone GM; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Odunsi K; Department of Gynecologic Oncology, Roswell Park Cancer Institute, New York, New York., McLean K; Division of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan., Lee AV; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania., Elishaev E; Department of Pathology, Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania., Edwards RP; Department of Obstetrics, Gynecology, & Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania., Oesterreich S; Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania. oesterreichs@upmc.edu.; Molecular Pharmacology Training Program, University of Pittsburgh, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Jul 15; Vol. 23 (14), pp. 3802-3812. Date of Electronic Publication: 2017 Jan 10.